Allmed Medical responded during an earnings briefing to the matter of CFO Huang Tiezhu joining Guangxi Liugong as head of finance just four days after his departure, stating that he resigned from the company for personal family reasons, and did not provide further explanation regarding investor questions about potential business disagreements. The company also addressed the long-term decline in its share price, noting that although first-quarter 2026 revenue grew 18.12% year-on-year and net profit attributable to the parent rose 25.95%, secondary market prices are influenced by multiple factors, and earnings growth does not necessarily drive market value higher. It will consider measures such as industry chain-related mergers and acquisitions at an appropriate time in the future. In addition, the company terminated a 66 million yuan land transfer deal, and the reclaimed land will be for its own use. This termination does not constitute a prior-period accounting error, and the related gains or losses will be recorded in the 2026 current period. Construction of the Indonesian factory is progressing normally and is still in the construction phase.
Allmed Medical Products Co Ltd Class ACFO departure and lack of explanation for business disagreements, plus share price decline despite earnings growth.
Guangxi Liugong Machinery Co Ltd